Article Figures & Data
Tables
Characteristics n (%) Age in years Mean±SD 34.2±16.6 Disease duration in months Mean±SD 25.7±8.9 Gender Male 40 (27.2) Female 107 (72.8) Clinical presentation Ocular 84 (57.1) Bulbar 40 (27.2) Generalized 23 (15.6) Anti AChR antibody Positive 130 (88.4) Anti-MuSK antibody Positive 8 (5.4) Double seronegative 11 (7.5) RNS Decremental response 65 (44.2) Normal 24 (16.3) Not done 58 (39.5) Treatment Pyridostigmine 14 (9.5) Azathioprine 4 (2.7) Pyridostigmine, prednisolone, with or without azathioprine 94 (63.9) Pyridostigmine, prednisolone, with or without azathioprine, and one dose IVIg 10 (6.8) Pyridostigmine, prednisolone, and mycophenolate 11 (7.5) Pyridostigmine, prednisolone, with or without azathioprine, and monthly IVIg 14 (9.5) Thymectomy Done 92 (62.6) Not done 55 (37.4) Treatment response Controlled 101 (68.7) Not controlled 46 (31.3) CT chest Prominent thymus 30 (20.4) Thymoma 17 (11.6) Normal 100 (68.0) Histopathology Thymic hyperplasia 57 (38.8) Thymoma 13 (8.8) Normal 22 (15) Clinical state at the end of follow up Ocular 7 (4.8) Bulbar 4 (2.7) Generalized 136 (92.5) Family history of MG Positive 6 (4.1) Negative 95 (64.6) Not recorded 46 (31.3) MG- Myasthenia gravis, AChR-acetylcholine receptors, RNS - repetitive nerve stimulation
Characteristics Ocular n=84 Bulbar n=40 Generalized n=23 P-value n (%) Age Mean ±SD 35.6±16.1 36.1±19.2 25.6±10.2 0.03* 0.043** Gender Male 25 (29.8) 11 (27.5) 4 (17.4) 0.497 Female 59 (70.2) 29 (72.5) 19 (82.6) Anti AChR antibody Positive 80 (95.2) 30 (75) 20 (87) 0.004 Anti-MuSK antibody Positive 0 (0) 8 (20) 0 (0) 0.000 Double seronegative 4 (4.8) 4 (10) 3 (13) NCS Decremental response 33 (39.3) 20 (50) 12 (52.2) 0.002 Normal 11 (13.1) 4 (10) 9 (39.1) Not done 40 (47.6) 16 (40) 2 (8.7) Treatment Pyridostigmine 7 (8.3) 2 (5) 5 (21.7) 0.000 Azathioprine 0 (0) 4 (10) 0 (0) Pyridostigmine, prednisolone, with or without azathioprine 65 (77.4) 18 (45) 11 (47.8) Pyridostigmine, prednisolone, with or without azathioprine, and one dose IVIg 2 (2.4) 8 (20) 0 (0) Pyridostigmine, prednisolone, and mycophenolate 2 (2.4) 6 (15) 3 (13) Pyridostigmine, prednisolone, with or without azathioprine, and monthly IVIg 8 (9.5) 2 (5) 4 (17.4) Thymectomy Done 55 (65.5) 18 (45) 19 (82.6) 0.009 Not done 29 (34.5) 22 (55) 4 (17.4) Treatment response Controlled 59 (70.2) 23 (57.5) 19 (82.6) 0.106 Not controlled 25 (29.8) 17 (42.5) 4 (17.4) CT chest Prominent thymus 19 (22.6) 11 (27.5) 0 (0) 0.003 Thymoma 9 (10.7) 8 (20) 0 (0) Normal 56 (66.7) 21 (52.5) 23 (100) Histopathology Thymic hyperplasia 35 (41.7) 13 (32.5) 9 (39.1) 0.000 Thymoma 9 (10.7) 4 (10) 0 (0) Normal 11 (13.1) 1 (2.5) 10 (43.5) Clinical state at the end of follow up Ocular 7 (8.3) 0 (0) 0 (0) 0.003 Bulbar 0 (0) 4 (10) 0 (0) Generalized 77 (91.7) 36 (90) 23 (100) Serology Positive 82 (97.6) 38 (95) 20 (87) 0.104 Negative 2 (2.4) 2 (5) 3 (13)